News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Updated Data With Oral Proteasome Inhibitor MLN9708 Reported In Newly Diagnosed Multiple Myeloma Patients


12/10/2013 10:29:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW ORLEANS & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The investigators reported a combined complete response and very good partial response (CR+VGPR) rate of 76 percent (46/62) and a 94 percent overall response rate (ORR; 58/62 = partial response). Stringent complete response (sCR) was reached in 75 percent of patients that attained CR. Overall, drug-related serious adverse events (SAEs) were reported in 28 percent of patients (18/64), and drug-related grade 3 adverse events (AEs) in 58 percent of patients (37/64). There were no drug-related grade 4 AEs. These data were presented today at the 55th American Society of Hematology (ASH) annual meeting held December 7-10 in New Orleans, LA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES